NCT02621359 is a Phase 3 clinical trial of Nitazoxanide in Dyspepsia, sponsored by Tanta University.

Who is sponsoring NCT02621359?

NCT02621359 is sponsored by Tanta University.

What drugs are being tested in NCT02621359?

Interventions in NCT02621359: Nitazoxanide, Levofloxacin, Doxycyclin, Omeprazole.

Is NCT02621359 still recruiting?

NCT02621359 is currently status unknown. Last updated 30 December 2017.

Last reviewed 2017-12-30 · How we verify

NCT02621359

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Two Week Nitazoxanidebased Quadruple Regimen for Helicobacter Pylori Therapy After Failure of Standard Triple Therapy: A Single Center Experience

Status unknown Phase 3 Last updated 30 December 2017

What this trial tests

Phase 3 trial testing Nitazoxanide in Dyspepsia in 100 participants. Status unknown.

Timeline

1 January 2015

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	Tanta University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 January 2015
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across Egypt

Drugs / interventions tested

Nitazoxanide (NITAZOXANIDE) — full drug profile →
Levofloxacin (Levofloxacin) — full drug profile →
Doxycyclin — full drug profile →
Omeprazole (omeprazole) — full drug profile →

Conditions studied

Dyspepsia — all drugs for Dyspepsia →

Sponsor

Tanta University

Who can join

Eligibility, any sex, with Dyspepsia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of patients with eradicated helicobacter
Time frame: 1 year
The total number of patients with eradicated helicobacter

Sponsor's own description

Helicobacter pylori (H. pylori) infection is a global health problem as it is associated with peptic ulcers, chronic gastritis, duodenitis, and stomach cancer. Therefore, the eradication of the pathogen is of critical importance to reduce H. pylori-related complications . However, due to increasing antibiotic resistance, eradication of Helicobacter pylori has become more challenging. With a great decline in the eradication rate of standard triple therapy for Helicobacter pylori to below 70% in many countries. Treatment with triple therapy, which is the most frequently recommended, fails to eradicate H. pylori in approximately 20% of cases .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.
Abd-Elsalam S, Kobtan A, El-Kalla F, Elkhalawany W, et al · · 2016 · cited 27× · PMID 27310977 · DOI 10.1097/md.0000000000003879

Verify or expand the search:

Other trials of Nitazoxanide

Trials testing the same drug.

NCT06993974 — Nitazoxanide in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07086937 — Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children · NA · completed
NCT06010992 — Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus · Phase 2 · unknown
NCT05368935 — Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects · Phase 1 · completed
NCT05116826 — Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients · Phase 1 · completed

Other recruiting trials for Dyspepsia

Currently open trials in the same condition.

NCT06941545 — High Resolution Gastric Mapping and Gastroduodenal Manometry · NA · recruiting
NCT07261228 — The Difference in Carbon Footprint Between Diagnostic Upper GI Endoscopy in Dyspeptic Patients Versus Therapeutic Upper · recruiting
NCT06755671 — A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms · recruiting
NCT06422052 — Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspep · recruiting
NCT05810168 — Traditional Dietary Advice Versus Low FODMAP Diet in Postprandial Functional Dyspepsia · NA · recruiting

Other Tanta University trials

Trials by the same sponsor.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02621359 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanta University
Last refreshed: 30 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02621359.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing